Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1148 in Septic Shock
NCT02317549Phase 2Terminated
- Sponsor
- Leading BioSciences, Inc.
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 2
01
Overview
A Phase 2 trial of LB1148 in septic shock, sponsored by Leading BioSciences, Inc.. Started Apr 2015; status: terminated.
02
Drugs
LB1148
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02317549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317549.